NAA and Cardiovascular Diseases

In recent years, the relationship between natural autoantibodies (NAAs) and cardiovascular diseases (CVDs) has attracted the interest of scientists. As a reputable supplier, Creative Biolabs focus on providing NAA testing and analysis services to customers around the world.

Introduction of CVDs

CVDs are multifactorial diseases that are the leading cause of mortality and morbidity worldwide. CVDs are primarily associated with atherosclerosis, which can lead to restricted blood flow and affect the function of the heart and nervous system. CVDs encompass many different diseases, such as coronary artery disease, hypertension, congenital heart disease, heart failure and vascular disease. The prevalence of CVDs are age-related, due to increases in plasma cholesterol on the one hand and arterial stiffness and peripheral vascular resistance on the other. In addition to this, dyslipidemia, obesity, diabetes, sedentary and unhealthy lifestyle, and genetic susceptibility are also important factors in the progression of CVDs. Therefore, healthy diets and good lifestyle habits are important for reducing cardiovascular morbidity and mortality.

Common CVDs

Pathological Mechanism of CVDs

Researchers have long hypothesized that immune dysregulation and chronic inflammation are beneficial in the development of atherosclerotic cardiovascular disease (ASCVD) pathology. ASCVD is closely related to lipoprotein deposits in large and medium arteries. The formation of fatty streaks at arterial branch points is an early event in ASCVD. Fat streaks mainly contain oxidized lipoprotein particles and lymphocytes. Streak composition and structural features change due to chronic superimposed inflammatory and healing responses. The advanced disease eventually leads to the formation of atherosclerotic plaques.

Schematic for NAA in atherogenesis.Fig.1 Schematic for NAA in atherogenesis. (Meier, 2018)

NAA in CVDs

There is increasing evidence that the immune system plays an important role in the development of cardiovascular disease. Both innate and adaptive immune mechanisms contribute to chronic inflammation in CVDs. Chronic inflammation and the resulting tissue damage have the potential to contribute to CVDs. In addition, autoantigen-reactive NAAs have been shown to modulate the natural history of multiple forms of CVDs, including dilated cardiomyopathy, atherosclerosis, and valvular heart disease. Several clinical studies have demonstrated the role of NAA in promoting CVDs. However, whether NAA might be an appropriate target for CVDs therapy remains to be explored.

Services in Creative Biolabs

Related Products in Creative Biolabs

Target Product name Cat.No
LDL autoantibodies Human Oxidized LDL Autoantibody (IgG) ELISA kit NAK-004
Cardiolipin autoantibodies Human Cardiolipin, Phosphatidyl Serine, Phosphatidyl Inositol and Phosphatidic acid Autoantibody (IgG&IgM) ELISA kit NAK-053
dsDNA autoantibodies Human dsDNA Autoantibody (IgG) ELISA kit NAK-035
dsDNA autoantibodies Human dsDNA Autoantibody (IgG&IgM&IgA) ELISA kit NAK-036

NAA may be a promising target in the treatment of CVDs. After years of accumulation, we have developed a mature NAA service platform that will facilitate your CVDs research. Please contact us in time for more information and detailed quotation.

Reference:

  1. Meier, L. A.; Binstadt, B. A. The contribution of autoantibodies to inflammatory cardiovascular pathology. Frontiers in immunology. 2018, 9: 911.

Choosing natural autoantibody (NAA) microarray to profile autoantibody repertoire and reveal novel disease's marker.

For Research Use Only | Not For Clinical Use

Related Services:

Products:

Resource:

Applications:

Online Inquiry
Inquiry